Abstract: The present invention relates to compositions and methods for enhancing T cell metabolism and activity for more effective adoptive T cell therapy. By expressing an chimeric antigen receptor and bispecific antibodies in T cells, the T cells are metabolically enhanced with improved cytotoxicity and resistance to immunosuppression imposed by tumor microenvironments. Certain aspects include modified T cells and pharmaceutical compositions comprising the modified cells for adoptive cell therapy and treating a disease or condition associated with enhanced immunity.

Abstract: The present invention relates to compositions and methods for enhancing T cell metabolism and activity for more effective adoptive T cell therapy. By expressing an intracellular signaling molecule in T cells, the T cells are metabolically enhanced with improved cytotoxicity and resistance to immunosuppression imposed by tumor microenvironments. One aspect includes a modified T cell and pharmaceutical compositions comprising the modified cells for adoptive cell therapy and treating a disease or condition associated with enhanced immunity.

Abstract: The present invention provides novel bispecific antibodies that bind to human CD30 and uses thereof. Methods of treating cancer using the bispecific antibodies described herein are also provided.

Abstract: The present invention provides novel bispecific antibodies that bind to human CD30 and uses thereof. Methods of treating cancer using the bispecific antibodies described herein are also provided.

Abstract: The present invention relates to compositions and methods for enhancing T cell metabolism and activity for more effective adoptive T cell therapy. By expressing an intracellular signaling molecule in T cells, the T cells are metabolically enhanced with improved cytotoxicity and resistance to immunosuppression imposed by tumor microenvironments. One aspect includes a modified T cell and pharmaceutical compositions comprising the modified cells for adoptive cell therapy and treating a disease or condition associated with enhanced immunity.

Abstract: The present disclosure provides soluble mutant PD-L1 peptides, polynucleotides and vectors encoding the peptides, and methods of using the peptides to elicit differentiation of regulatory T cells.

Abstract: Methods and compositions for treating cancer in a subject in need thereof. The method includes administering to the subject an effective amount of a composition comprising Tumor-Targeting Effectors (TITE) derived from a culture comprising a bispecific antibody armed activated T cell (BAT) and a cancer cell, to thereby treat cancer in the subject.

Abstract: Provided are methods and compositions for treating disease and/or disorders associated with inflammatory conditions, such as autoimmune diseases, graft-vs-host diseases, and/or organ graft rejection (collectively AGO), In some embodiments, the methods include isolating peripheral blood mononuclear cells from a patient suffering from AGO, arming a population of TREGS with a bispecific antibody directed at TREG cells and at target antigens on pancreatic islet cells or other AGO inflamed target tissues under conditions, wherein generation of TREGS, bispecific antibody is used to arm ATREGS and target cells expressing autoimmune antigens, ATREG cells binding to target cells expressing autoimmune antigens, suppression of inflammatory activity by immune cells in the tissue microenvironment by ATREGS, and infusing a composition comprising the ATREGS armed with a bispecific antibody into the subject to thereby treat the AGO in the patient.

Abstract: Methods and compositions for treating cancer in a subject in need thereof, comprising administering to the subject an effective amount of a targeted activated T cell, such as a bispecific antibody armed activated T cell (BAT), alone or in combination with an effective amount or a subtherapeutic amount of an additional therapeutic agent, wherein the targeted activated T cell selectively binds a cell of the cancer in the subject.

Abstract: The present invention provides novel bispecific antibodies that bind to human CD30 and uses thereof. Methods of treating cancer using the bispecific antibodies described herein are also provided.

Abstract: The present invention provides methods for inducing and expanding anti-tumor immunity leading to enhanced clinical and immunotherapeutic responses. The invention also provides novel compositions and methods for the treatment of cancer.

Abstract: This invention provides compositions of matter, articles of manufacture and methods for delivering and/or affixing a stem cell to a target tissue. This invention also provides related nucleic acids, vectors, cells, methods of production, and kits.

Abstract: The present invention relates to compositions and methods for enhancing T cell metabolism and activity for more effective adoptive T cell therapy. By expressing an intracellular signaling molecule in T cells, the T cells are metabolically enhanced with improved cytotoxicity and resistance to immunosuppression imposed by tumor microenvironments. One aspect includes a modified T cell and pharmaceutical compositions comprising the modified cells for adoptive cell therapy and treating a disease or condition associated with enhanced immunity.

Abstract: The present invention relates to compositions and methods for enhancing T cell metabolism and activity for more effective adoptive T cell therapy. By expressing an chimeric antigen receptor and bispecific antibodies in T cells, the T cells are metabolically enhanced with improved cytotoxicity and resistance to immunosuppression imposed by tumor microenvironments. Certain aspects include modified T cells and pharmaceutical compositions comprising the modified cells for adoptive cell therapy and treating a disease or condition associated with enhanced immunity.

Abstract: This invention provides compositions of matter, articles of manufacture and methods for delivering and/or affixing a stem cell to a target tissue. This invention also provides related nucleic acids, vectors, cells, methods of production, and kits.

Abstract: The invention relates to compositions and methods for treating a host infected with a pathogen. The composition comprising a population of polyclonal bispecific binding molecules that can target and eliminate a host cell infected with the pathogen. Methods for activating and arming cytotoxic immune cells with the composition for use in treating a patient infected with a pathogen are also provided.

Abstract: This invention provides compositions of matter, articles of manufacture and methods for delivering and/or affixing a stem cell to a target tissue. This invention also provides related nucleic acids, vectors, cells, methods of production, and kits.

Abstract: The invention relates to compositions and methods for treating a host infected with a pathogen. The composition comprising a population of polyclonal bispecific binding molecules that can target and eliminate a host cell infected with the pathogen. Methods for activating and arming cytotoxic immune cells with the composition for use in treating a patient infected with a pathogen are also provided.

Abstract: Provided are compositions comprising activated T cells and activated T cells armed with bispecific antibodies directed at cancer antigens which are poor responders to alloantigen, and methods of using the compositions to help engraftment and improve anti-tumor effects.

Abstract: This invention provides compositions of matter, articles of manufacture and methods for delivering and/or affixing a stem cell to a target tissue. This invention also provides related nucleic acids, vectors, cells, methods of production, and kits.